A Pilot Investigation of the Nasal Mucosal Absorption, Retention, and Metabolism of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray When Each Formulation Is Administered to Currently Symptomatic Patients (18 Years or Older) With Documented Perennial Allergic Rhinitis (PAR).

University of Chicago1 个研究点分布在 1 个国家开始时间: 2009年2月最近更新: 2013年6月7日

适应症

干预措施

试验速览

阶段: 4 期
状态: 撤回
发起方: University of Chicago
试验地点: 1
主要终点: levels of ciclesonide in biopsy tissue

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to measure the amount of a nasal steroid spray (ciclesonide) absorbed by the tissue in the nose 2 hours after having this study drug sprayed in the nose

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Single Group
主要目的: Basic Science
盲法: Single (Participant)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Males and females 18 years of age or older.
•History of perennial allergic rhinitis for at least 1 year prior to screening.
•Positive skin test to perennial allergen.

排除标准

•Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
•Pregnant or lactating women.
•Upper respiratory infection within 14 days of study start.
•Active asthma requiring treatment with inhaled or systemic steroids.
•Use of any form of nasal spray during the previous month.